---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-061344"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:06:01.666090+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Zai Lab reports FY2021 results; financial details not provided in 8-K exhibit

## Summary
- Announced financial results for FY2021; specific revenue and EPS figures not provided in the filing.
- Forecasts peak-year sales from lung and GI cancer franchises could reach $2.5–3B by 2030.
- Proposed share subdivision of ordinary shares (1:10) to increase liquidity on HKEX; shareholder vote sought.
- Plans to submit NDA for efgartigimod in gMG in China in mid-2022; multiple clinical milestones.
- Entered license agreements for KarXT (neuroscience) and BLU-945/701 (EGFR NSCLC) in Greater China.

## SEC filing metadata
- accession: 0001193125-22-061344
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000119312522061344/0001193125-22-061344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000119312522061344/d258445d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-061344
- JSON: https://secwatch.observer/filing/0001193125-22-061344.json
- Plain text: https://secwatch.observer/filing/0001193125-22-061344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.